Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
04:05pm, Wednesday, 08'th Sep 2021
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
04:05pm, Tuesday, 07'th Sep 2021
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd A
Now May Be the Big Moment for These 2 COVID Stocks
06:00am, Thursday, 02'nd Sep 2021
Their products are seeing a surge in demand.
Antibody drugs take off in new Covid surge
03:23pm, Tuesday, 31'st Aug 2021
Meg Tirrell joins The Exchange with more information about Covid antibody treatments and the increasing demand for these drugs in places where the delta variant is surging. For access to live and excl
Coronavirus antibody drugs take off
10:49am, Monday, 30'th Aug 2021
CNBC's Meg Tirrell reports on the surge in Covid antibody drug orders.
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia
12:05pm, Monday, 23'rd Aug 2021
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab, a monoclonal antibody for COVID-19. The ap
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
08:30am, Monday, 23'rd Aug 2021
– First monoclonal antibody authorized in Australia – – First monoclonal antibody authorized in Australia –
VIR Stock Price Increases Over 10% Pre-Market: Why It Happened
06:30am, Friday, 06'th Aug 2021
The stock price of Vir Biotechnology, Inc. (Nasdaq: VIR) increased by over 10% pre-market. This is why it happened.
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Beat Estimates
07:01pm, Thursday, 05'th Aug 2021
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 167.65% and 205.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock
Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment
08:51am, Wednesday, 28'th Jul 2021
Shares of Vir Biotechnology Inc. gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline said the European Commission purchased 220,00 doses of their investigational COVID-
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
06:20am, Wednesday, 28'th Jul 2021
LONDON and SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
04:05pm, Thursday, 22'nd Jul 2021
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter e
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
12:26pm, Friday, 16'th Jul 2021
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy
09:46am, Thursday, 15'th Jul 2021
Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) in
These COVID Therapies Appear to Be the Best and Worst at Treating New Variants
06:04am, Saturday, 03'rd Jul 2021
Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.
